Clinical value of soluble urokinase-type plasminogen activator receptor (SuPAR) as a biomarker of disease activity in Behcet’s disease
Vol. 29 No. 4 (2021), Original Articles
Vol. 29 No. 4 (2021)

Clinical value of soluble urokinase-type plasminogen activator receptor (SuPAR) as a biomarker of disease activity in Behcet’s disease

Original Articles
https://doi.org/10.35465/29.4.2021.pp47-52
Published December 6, 2021
Amal Hassan Rizk
Rheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, Egypt
Walaa Abdelfattah
Clinical and Chemical Pathology Department. Faculty of Medicine, Cairo University,
Arwa O. Al-Shaarawy
Rheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, Egypt
Nora Yousry Elsaid
Cairo University
PDF EN

Keywords

Behçet's disease, suPAR, disease activity, inflammation.

How to Cite

Rizk, A., Abdelfattah, W., Al-Shaarawy, A., & Elsaid, N. (2021). Clinical value of soluble urokinase-type plasminogen activator receptor (SuPAR) as a biomarker of disease activity in Behcet’s disease. Rheumatology (Bulgaria), 29(4), 47-52. https://doi.org/10.35465/29.4.2021.pp47-52
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Background: Behçet's disease (BD) is a chronic multisystemic vasculitic disease of unknown pathogenesis. Diagnosis and disease activity measurement has always been a challenge. Soluble urokinase plasminogen activator receptor (suPAR) is showing an increased utility as a promising diagnostic and prognostic inflammatory biomarker in different systemic inflammatory disorders.

Objectives: To study the clinical value of plasma Soluble urokinase plasminogen activator receptor (suPAR) in patients with Behçet's disease, and if it can be used as a measure to disease activity.  Methods: According to the International Criteria for Behcet's Disease (ICBD), fifty adult Behçet's disease patients were enrolled in the study, and forty healthy adult subjects were included in a case-control study. An enzyme-linked immunosorbent assay was used to obtain quantitative data. Results: The suPAR level was not statistically different between the patients with BD patients and the controls. No correlation was found between suPAR levels and disease activity (BDFAC). Conclusion: Very few studies analyzed the clinical value of suPAR level in patients with BD and its correlation with disease activity. Our results show that suPAR does not seem to play a role in the disease mechanism of BD.

Keywords: Behçet's disease, suPAR, disease activity, inflammation.

 

 

https://doi.org/10.35465/29.4.2021.pp47-52
PDF EN

References

  1. -Kokturk A. Clinical and Pathological Manifestations with Differential Diagnosis in Behçet's Disease. Patholog Res Int 2012:690390. Doi:10.1155/2012/690390.
  2. - Kaufman WS, McNamara EK and Jorizzo JL. “Behçet's Disease” Kelley and Firestein's Textbook of Rheumatology 2017 pp.1589 —1596.
  3. - Türsen U. Pathophysiology of the Behçet's Disease. Patholog Res Int. 2012:493015. Doi:10.1155/2012/493015.
  4. - Iba T and Levy JH. “Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis.” J Thromb Haemost.; 2018 Feb;16(2):231-241. PMID: 29193703 Doi: 10.1111/jth.13911
  5. - Periayah MH, Halim AS and Mat Saad AZ. Mechanism Action of Platelets and Crucial Blood Coagulation Pathways in Hemostasis. International Journal of Hematology-Oncology and Stem Cell Research; 2017,11(4):319-327.PMID: 29340130; PMCID: PMC5767294.
  6. - Graf C and Ruf W. “Tissue factor as a mediator of coagulation and signaling in cancer and chronic inflammation.” Thromb Res; 2018Apr;164 Suppl 1: S143-S147. Doi: 10.1016/j.thromres.2018.01.023
  7. - Jaiswal RK, Varshney AK and Yadava PK. “Diversity and functional evolution of the plasminogen activator system.” Biomed Pharmacother; 2018, Feb; 98:886-898. Doi: 10.1016/j.biopha.2018.01.029.
  8. - Ventorp F, Gustafsson A, Träskman-Bendz L et al. “Increased Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in Plasma of Suicide Attempters.” PLoS One; 2015, Oct 9;10(10): e0140052 Doi: 10.1371/journal.pone.0140052. eCollection 2015.
  9. - Vasarhelyi B, Toldi G, and Balog A “The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders” EJIFCC; 2016 Apr 20;27(2):122-9. PMID: 27683525 PMCID: PMC4975228.
  10. -Desmedt S, Desmedt V, Delanghe JR, et al. “The intriguing role of soluble urokinase receptor in inflammatory diseases.” Crit Rev Clin Lab Sci; 2017 Mar;54(2):117-133. Doi: 10.1080/10408363.2016.1269310.
  11. -Indumati V, Vijay V, Krishnaswamy D, et al.“Serum levels of soluble urokinase plasminogen activator receptor(suPAR) as a marker of tuberculosis treatment efficacy.” Indian J Tuberc; 2017; Jul;64(3):206-211. Doi: 10.1016/j.ijtb.2017.01.012. Epub 2017 Feb 22
  12. -Sidenius N, Sier CF, Ullum H et al. “Serum Level of Soluble Urokinase-Type Plasminogen Activator Receptor Is a Strong and Independent Predictor of Survival in Human Immunodeficiency Virus Infection.” Blood;2000, 96(13): 4091–95. PMDI: 11110678
  13. - Geboers DG, de Beer FM, Tuip-de Boer AM, et al “Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients.” Intensive Care Med; 2015, 41:1281–90. Doi: 10.1007/s00134-015-3924-9
  14. -Hildenbrand R, Allgayer H, Marx A et al. Modulators of the urokinase-type plasminogen activation system for cancer. Expert Opin Investig Drugs; 2010,19(5):641–652. Doi:10.1517/13543781003767400.
  15. - Dass K, Ahmad A, Azmi AS et al. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev; 2008; 34:122–36. Doi: 10.1016/j.ctrv.2007.10.005.
  16. -Bene MC, Castoldi G, Knapp W et al. CD87(urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia; 2004, 18:394–400. Doi: 10.1038/sj.leu.2403250.
  17. -Qin DD, Song D, Huang J et al “Plasma-Soluble Urokinase-Type Plasminogen Activator Receptor Levels Are Associated with Clinical and Pathological Activities in Lupus Nephritis: A Large Cohort Study from China.” Lupus; 2015,24(6): 546–57 Doi: 10.1177/0961203314558857. Epub 2014 Nov 18.
  18. - Thornton S, Rossing P, Eugen-Olsen J et al “Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells”. Blood Adv. 2017; Mar 21;1(9):545-556. Doi: 10.1182/bloodadvances.2016004002.
  19. -Riisbro R, Christensen IJ, Hogdall C et al “Soluble urokinase plasminogen activator receptor measurements: influence of sample handling”, Int. J. Biol. Mark. 16 (2001) 233–239. Doi: 10.1182/bloodadvances.2016004002.
  20. -Andersen O, Eugen-Olsen J, Kofoed K et al “Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy”, J. Med. Virol. 80 (2008) 209–216. Doi: 10.1002/jmv.21114.
  21. - International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338-347. Doi:10.1111/jdv.12107.
  22. -Hatemi G, Silman A, Bang D, et al EULAR recommendations for the management of Behçet disease Annals of the Rheumatic Diseases 2008;67: 1656-1662. Doi: 10.1136/ard.2007.080432.
  23. -Bhakta B, Hamuryudan V, Brennan P et al “Assessment of disease activity in Behçet's disease”. In: Wechsler B, Godeau P, eds. Excerpta Medica International Congress Series 1037, 611.Amsterdam: Elsevier Science;1993 :235–40.
  24. - Cho SB, Cho S, Bang D “New insights in the clinical understanding of Behçet's disease.” Yonsei Med J.;2012, 53(1):35‐42. Doi:10.3349/ymj.53.1.35
  25. - Thuno, Macho B and Eugen-Olsen J “suPAR: The Molecular Crystal Ball.” Disease markers; 2009, 27(3): 157–72. Doi: 10.3233/DMA-2009-0657.
  26. - Birengel S, Yalçındağ FN, Yalçındağ A, et al, “Urokinase plasminogen activator receptor levels in Behcet's disease. Thromb Res.; 2011, Sep;128(3):274-6. Doi: 10.1016/j.thromres.2011.03.003.
  27. - Kurtipek G.S, Kesli R, Akyurek F.T .et al “Plasma‐soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity” Int J Rheum Dis.;2016, Apr;21(4):866-870. Doi:10.1111/1756-185X.12873.
  28. - Tamura Y, Kawao N, Yano M. et al “Role of Plasminogen Activator Inhibitor-1 in Glucocorticoid-Induced Diabetes and Osteopenia in Mice” Diabetes; 2015, Jun; 64(6): 2194-2206. Doi: 10.2337/db14-1192.
  29. - Enocsson H, Wirestam L, Dahle C, et al. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity. 2020 Jan; 106:102340. Doi: 10.1016/j.jaut.2019.102340.
  30. -Enocsson H, Lukic T, Ziegelasch M et al “Serum levels of the soluble urokinase plasminogen activator receptor (suPAR) correlates with disease activity in early rheumatoid arthritis and reflects joint damage over time”, Translational Research, 2021, ISSN 1931-5244, Doi: https://doi.org/10.1016/j.trsl.2021.02.007.
  31. - Nowatzky J and Chajek-Shaul T “Biomarkers in Behçet's Disease: Diagnosis and Disease Activity” Int J Clin Rheumatol;2009, 4(3):271-286. Doi: http://dx.doi.org/10.2217/ijr.09.22.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.